Please assess the completion status of the following clinical trial:

Trial Title: Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Have at least a one-year history of seasonal allergic rhinitis which previously required treatment for tree and/or grass pollen~* Have a positive skin test response to an appropriate tree and/or grass seasonal allergen within the last year.~* Must be free of any clinically significant disease other than seasonal allergic rhinitis.~* Must be pre-menarcheal.~Exclusion Criteria:~* History of asthma which requires chronic use of inhaled or systemic corticosteroids.~* Current or history of frequent, clinically significant sinusitis or chronic purulent postnasal drip.~* History of rhinitis medicamentosa.~* History of clinically significant nasal candidiasis.~* History of multiple drug allergies or allergy/intolerance to corticosteroids or antihistamines.~* History of upper respiratory tract or sinus infection that required antibiotic therapy within the previous 2 weeks, or viral upper respiratory infection within 7 days prior to Screening.~* History of nasal structural abnormalities, including large nasal polyps and marked septal deviation, that significantly interfere with nasal air flow.~* History of dependence upon nasal, oral or ocular decongestants, or nasal topical antihistamines.~* History of investigational drug use in the last 30 days.~* History of immunotherapy (desensitizing therapy), unless on a stable maintenance schedule for at least one month prior to Screening.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- MFNS 25 mcg QD (Type: EXPERIMENTAL): Mometasone furoate nasal spray 12.5 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
- MFNS 100 mcg QD (Type: EXPERIMENTAL): Mometasone furoate nasal spray 50 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
- MFNS 200 mcg QD (Type: EXPERIMENTAL): Mometasone furoate nasal spray 100 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
- BDP 84 mcg BID (Type: ACTIVE_COMPARATOR): Beclomethasone dipropionate nasal spray 42 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo nasal spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).